What are the recommended management steps and medication dosing for type 2 diabetes, including lifestyle modification, metformin, second‑line agents (GLP‑1 receptor agonists, SGLT2 inhibitors, sulfonylureas, DPP‑4 inhibitors), and insulin therapy?

Type 2 Diabetes Management and Treatment Doses

Metformin remains the first-line pharmacologic agent for type 2 diabetes, titrated to 2,000 mg daily as tolerated, combined with lifestyle modifications including at least 150 minutes of weekly physical activity and a 7% weight loss goal. 1

Initial Management Strategy

Lifestyle Foundation

• Physical activity: Minimum 30-60 minutes of moderate to vigorous activity at least 5 days per week, plus strength training on at least 3 days per week 1
• Weight loss target: Initial goal of 7% of baseline body weight 2
• Dietary approach: Low-fat, reduced-calorie diet emphasizing nutrient-dense, high-quality foods while decreasing calorie-dense, nutrient-poor foods, particularly sugar-added beverages 1, 2

First-Line Pharmacologic Therapy

Metformin initiation and dosing:

• Start metformin at diagnosis unless contraindicated (eGFR <30 mL/min per 1.73 m²) 1
• Titrate up to 2,000 mg per day as tolerated 1
• Continue metformin when eGFR ≥30 mL/min per 1.73 m² 1

Second-Line Agent Selection Based on Clinical Context

For Patients with Established Cardiovascular Disease or High CV Risk

SGLT2 inhibitors are the preferred second-line agent:

• Initiate when eGFR ≥20 mL/min per 1.73 m² and continue until dialysis or transplantation 1
• Provide cardiovascular mortality reduction, heart failure hospitalization reduction, and kidney disease progression prevention 1
• Note: Glycemic benefits diminish at eGFR <45 mL/min per 1.73 m² 1

GLP-1 receptor agonists as alternative or addition:

• Reduce all-cause mortality, major adverse cardiovascular events, and stroke risk 1
• Prioritize in patients with increased stroke risk or when weight loss is a primary treatment goal 1
• High glucose-lowering efficacy with semaglutide once weekly showing greatest effect, followed by dulaglutide and liraglutide 1

For Patients with Heart Failure

SGLT2 inhibitors are mandatory:

• Recommended for both reduced and preserved ejection fraction heart failure 1
• Prevent heart failure hospitalizations and provide glycemic management 1

For Patients with Chronic Kidney Disease

SGLT2 inhibitors for eGFR 20-60 mL/min per 1.73 m²:

• Minimize CKD progression, reduce cardiovascular events, and decrease heart failure hospitalizations 1
• Must be initiated when eGFR ≥20 mL/min per 1.73 m² 1

GLP-1 receptor agonists for advanced CKD (eGFR <30 mL/min per 1.73 m²):

• Preferred for glycemic management due to lower hypoglycemia risk and cardiovascular event reduction 1

For Patients Without Cardiovascular or Kidney Disease

Choice based on A1C elevation and patient factors:

If A1C is 1.5-2.0% above target, consider initial combination therapy with metformin plus one of the following 1:

• SGLT2 inhibitor: Provides weight loss, blood pressure reduction, no hypoglycemia risk 1
• GLP-1 receptor agonist: High efficacy, weight loss, minimal hypoglycemia risk 1
• DPP-4 inhibitor: Moderate efficacy, weight neutral, minimal hypoglycemia risk as monotherapy (but avoid due to lack of mortality benefit) 1
• Sulfonylurea: High efficacy, low cost, but causes weight gain and hypoglycemia risk 1
• Thiazolidinedione (pioglitazone 15-30 mg): High efficacy, best glycemic durability, but causes fluid retention, weight gain, bone fracture risk 1

Important: The American College of Physicians strongly recommends against adding DPP-4 inhibitors to metformin, as they do not reduce morbidity or all-cause mortality. 1

Insulin Therapy Initiation

Immediate Insulin Indications

Start insulin immediately when:

• Blood glucose ≥300 mg/dL (16.7 mmol/L) OR A1C ≥10% (86 mmol/mol) 1
• Presence of catabolic features: unexpected weight loss, hypertriglyceridemia, ketosis 1
• Symptoms of hyperglycemia: polyuria, polydipsia 1
• Diabetic ketoacidosis or marked ketosis present 1

Basal Insulin Dosing

Initial dosing:

• Start at 10 units or 0.1-0.2 units/kg body weight 1
• Alternative starting dose: 0.5 units/kg/day, titrate every 2-3 days based on blood glucose monitoring 1
• Use with metformin and possibly one additional noninsulin agent 1

Insulin formulations:

• Long-acting analogs (glargine, detemir, degludec) preferred over NPH due to reduced nocturnal hypoglycemia risk 1
• U-300 glargine and U-200 degludec have longer duration than U-100 formulations 1

Intensification Beyond Basal Insulin

When basal insulin reaches 0.5 units/kg/day and A1C remains above target:

Option 1: Add GLP-1 receptor agonist (preferred) 1

• Associated with weight loss and less hypoglycemia compared to prandial insulin 1
• Fixed-ratio combinations available: insulin glargine/lixisenatide, insulin degludec/liraglutide 1

Option 2: Add SGLT2 inhibitor 1

• Lowers blood glucose without increasing insulin doses, weight gain, or hypoglycemia 1
• May require insulin dose reduction to prevent hypoglycemia 1

Option 3: Add prandial insulin 1

• Single injection of rapid-acting insulin (lispro, aspart, glulisine) before largest meal 1
• If inadequate, progress to multiple daily injections with basal and premeal bolus insulins 1

Option 4: Switch to premixed insulin 1

• Twice-daily premixed insulin (70/30 NPH/regular, 70/30 aspart mix, 75/25 or 50/50 lispro mix) 1
• Less flexible than basal-bolus regimens 1

Medication-Specific Dosing Details

SGLT2 Inhibitors

• Use with caution when combined with diuretics and/or ACE inhibitors/ARBs due to acute kidney injury, dehydration, and orthostatic hypotension risk 1
• Canagliflozin specifically associated with increased amputation risk (HR 1.97) and fracture risk (HR 1.26) 1

GLP-1 Receptor Agonists

• Once-weekly options: Semaglutide (highest efficacy), dulaglutide, exenatide extended-release 1
• Once-daily options: Liraglutide, lixisenatide 1
• Twice-daily option: Exenatide 1
• Contraindicated with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 1

DPP-4 Inhibitors

• Dose adjustment required based on renal function (except linagliptin) 1
• When added to sulfonylurea, hypoglycemia risk increases 50% 1

Sulfonylureas

• Inexpensive and widely available with high glucose-lowering efficacy 1
• Associated with weight gain, hypoglycemia risk, and lack of durable glycemic effect 1

Thiazolidinediones

• Pioglitazone 15-30 mg reduces weight gain and edema compared to higher doses 1
• Contraindicated in congestive heart failure due to fluid retention risk 1
• Associated with bone fracture risk and possibly bladder cancer 1

Monitoring and Adjustment

• A1C measurement: Every 3 months 1
• A1C target: <7% (53 mmol/mol) for most patients on oral agents alone 1
• Medication reassessment: Every 3-6 months, adjusting based on glycemic and weight goals 1
• Insulin tapering: When meeting glucose targets on insulin plus metformin, decrease insulin dose 10-30% every few days over 2-6 weeks 1

Critical Pitfalls to Avoid

• Do not delay insulin when blood glucose ≥300 mg/dL or A1C ≥10%, or when catabolic features present 1
• Do not add DPP-4 inhibitors as they lack mortality benefit compared to SGLT2 inhibitors and GLP-1 receptor agonists 1
• Do not continue metformin when eGFR <30 mL/min per 1.73 m² 1
• Do not initiate SGLT2 inhibitors when eGFR <20 mL/min per 1.73 m² 1
• Reduce insulin doses when adding SGLT2 inhibitors to prevent hypoglycemia 1